Loading...
XETRFYB
Market cap964mUSD
Dec 23, Last price  
52.50EUR
1D
2.34%
1Q
5.21%
Jan 2017
119.76%
IPO
601.87%
Name

Formycon AG

Chart & Performance

D1W1MN
XETR:FYB chart
P/E
12.24
P/S
11.94
EPS
4.29
Div Yield, %
0.00%
Shrs. gr., 5y
11.24%
Rev. gr., 5y
12.56%
Revenues
78m
+82.83%
20,00049,2520138,430276,17312,585,01716,924,98719,532,99529,003,53642,993,51733,157,17534,226,93936,613,00042,497,00077,696,000
Net income
76m
+110.59%
-191,0000-1,290,00000860,326577,518-4,066,129-1,581,3827,098,615-2,293,287-5,925,705-13,290,00035,992,00075,795,000
CFO
-10m
L-48.15%
0038,6002,159,000-16,651,000-32,166517,000-5,038,400-4,171,19813,298,900-1,506,100-5,208,000-13,541,000-18,994,000-9,848,000
Earnings
Aug 11, 2025

Profile

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
URL
https://www.formycon.com/
IPO date
Dec 20, 2010
Employees
224
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
77,696
82.83%
42,497
16.07%
36,613
6.97%
Cost of revenue
77,677
60,225
50,441
Unusual Expense (Income)
NOPBT
19
(17,728)
(13,828)
NOPBT Margin
0.02%
Operating Taxes
3,275
604
(917)
Tax Rate
17,236.84%
NOPAT
(3,256)
(18,332)
(12,911)
Net income
75,795
110.59%
35,992
-370.82%
(13,290)
124.28%
Dividends
Dividend yield
Proceeds from repurchase of equity
70,488
1,763
1,512
BB yield
-7.79%
-0.15%
-0.23%
Debt
Debt current
21,671
21,715
877
Long-term debt
16,816
27,594
8,812
Deferred revenue
7,594
Other long-term liabilities
187,690
299,339
Net debt
(155,598)
(239,217)
(39,105)
Cash flow
Cash from operating activities
(9,848)
(18,994)
(13,541)
CAPEX
(21,196)
(26,759)
(941)
Cash from investing activities
(17,380)
(37,070)
(3,929)
Cash from financing activities
44,443
40,855
491
FCF
(4,067)
(18,195)
(17,822)
Balance
Cash
27,041
9,820
25,179
Long term investments
167,044
278,706
23,615
Excess cash
190,200
286,401
46,963
Stockholders' equity
89,880
356,580
55,891
Invested Capital
630,047
418,719
14,211
ROIC
ROCE
0.00%
EV
Common stock shares outstanding
16,049
13,884
11,043
Price
56.40
-34.80%
86.50
46.61%
59.00
11.32%
Market cap
905,142
-24.63%
1,200,955
84.33%
651,516
11.75%
EV
749,544
961,738
612,411
EBITDA
1,906
(15,866)
(12,216)
EV/EBITDA
393.25
Interest
94
143
173
Interest/NOPBT
494.74%